NO. The problem is that there are so many treatments, which improve survival but are sub-optimal in effect for the patient.
Pharmaceutical drugs do NOT create new cells. IF there were still the patient cohort who were untreated, then MSB would have no problem sailing through the trials. IMO.
But don't let the secret out. Best to trigger emotional retail investors and clean up while you can. AGAIN.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-318
-
- There are more pages in this discussion • 758 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 274918 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 974 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |